Sylvain Sachot

Sylvain Sachot is a Partner at Asabys Partners and serves as a Board Member at Gradient Denervation Technologies. Here's a detailed profile of Sylvain Sachot:

Professional Background

Sylvain Sachot joined Asabys Partners at its inception in 2018.4 As a Partner at Asabys, he is involved in sourcing, executing, and managing investments in the biopharma and medtech sectors.4

Board Positions

Sylvain currently serves on the board of directors for several companies:

• Gradient Denervation Technologies
• Anaconda Biomed
• Orikine Bio

He also holds observer positions on the boards of SpliceBio and Medlumics.4

Education

Sylvain has a strong academic background:

• PhD in Molecular Medicine from the University of Nantes
• Master's degree in biotechnology (with honors) from University Paris XII
• MBA from Esade Business School in Barcelona45

Previous Experience

Before joining Asabys Partners, Sylvain spent a decade in academic research:

• Postdoctoral fellow in the Department of Genetics and Genomic Sciences at Mount Sinai School of Medicine in New York
• Completed his doctoral thesis at INSERM (French National Institute of Health and Medical Research)4

Expertise

Sylvain's expertise spans several areas:

• Biotechnology
• Gene and cell therapy
• Lysosomal storage disorders
• Biopharma and medtech industries1

Language Skills

Sylvain has full professional proficiency in French, English, and Spanish.1

Recent Investment

Sylvain recently announced Asabys Partners' investment in Gradient Denervation Technologies, leading a €14 million Series A financing round.23 He expressed confidence in the company's potential to develop a first-in-class treatment for patients suffering from heart failure and elevated pulmonary pressures.23